(firstQuint)Abiraterone-Rechallenge Study for CRPC Patients.

 To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.

 CRPC patients with prior response to abiraterone (confirmed PSA Response) and progression can be re-challenged with abiraterone.

 Patients may have received treatment with docetaxel, enzalutamide and radium-223.

.

 Abiraterone-Rechallenge Study for CRPC Patients@highlight

To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.

